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AbstrAct
background: cervical cancer is a public health problem in latin america. radiotherapy plays a fundamental role both as 
definitive or adjuvant treatment. there are important intra and inter-country differences regarding access and availability of 
radiotherapy facilities in this region. 
the aim of a study was to standardize the basic clinical and technical criteria for the radiation treatment of patients with cc in 
chile and provide a guide for latin american radiation Oncologists.
Materials and methods: Forty-one expert radiation oncologists from the chilean radiation Oncology Society made a con-
sensus using the Delphi methodology. 
results: there was a high degree of agreement for each of the recommendations. those with the lowest percentage were 
related to the definition of the conformal 3D technique as the standard for definitive external radiotherapy (81%) and the 
criteria for extended nodal irradiation (85%). 
conclusions: these recommendations present an updated guide for radiotherapy treatment of patients with cervical cancer 
for latin america. those should be implemented according to local resources of each institution.
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Cervical cancer (CC) is an important prob-
lem for public health in Latin America. Accord-
ing to GLOBOCAN, it’s the sixth most frequent 
malignancy in Chilean’s women, with incidence of 
12.2/100,000 women, (age-adjusted rate) and mor-
tality of 5.0/100,000 [1]. Early diagnosis screening 
with the Papanicolaou test is essential but the cov-
erage of the Chilean population is only about 59%, 
with zones that fluctuate between 72.2% (Los Ríos’s 
region) and 45.5% (Antofagasta’s Region) [2]. Ra-
diation therapy plays a fundamental role in CC for 
the primary (definitive) and adjuvant (postopera-
tive) settings, with treatment schemes that combine 
external beam radiotherapy (EBRT), high dose rate 
(HDR) or low dose rate (LDR) brachytherapy, and 
concomitant chemotherapy (CCT) [2]. The acceler-
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ated evolution of the technology in imaging and ra-
diation equipment during the last decades has im-
plied a paradigm shift in different types of cancer, 
including the gynecological ones. Latin America is 
a region with different realities within and between 
countries regarding access and availability of ra-
diotherapy facilities [3–5]; therefore, it is of high 
importance to have a regional consensus to define 
treatment strategies. The present consensus aims to 
standardize the basic clinical and technical criteria 
for the radiation treatment of patients with CC in 
Chile and provide a guideline for Latin American 
Radiation Oncologists.
Materials and methods 
The board of the Chilean Society of Radiation 
Oncology (SOCHIRA) convened national experts 
in radiation oncology with experience in the man-
agement of patients with CC. To generate a national 
consensus.  We used a three phase modified Delphi 
method [6].
The first phase was an online survey developed 
to ask for the management of different clinical cases 
and common management practices. We distribut-
ed the survey by e-mail to national specialists using 
a digital platform. Subsequently, national specialists 
were called to make a review of the literature, in-
cluding PUBMED database, recent publications in 
conferences of the specialty and recommendations 
of international groups in order to prepare propos-
als for recommendations based on the evidence and 
consider the opinions or comments provided by 44 
national experts through the online survey previ-
ously indicated. 
In the second phase, the proposal for final rec-
ommendations based on the answers from the first 
phase was distributed to 89 specialists in oncologi-
cal radiotherapy from the country.
Participants had to specify anonymously their 
level of agreement to the statements using a 5-point 
Likert’s scale [7]: 1 = Strongly disagree, 2 = Dis-
agree, 3 = Neither agree nor disagree, 4 = Agree, 
5 = Strongly agree.
The consensus in a recommendation was estab-
lished if more than 66% of the answers were 1 and 
2, or 4 and 5 for each question, according the sug-
gestions of the literature [6, 8]. Finally, the third 
phase was carried out in person to review the re-
sults of online voting and define consensus on those 
statements that reached only partial consensus in 
phase 2. Degrees of recommendation and levels of 
evidence were assigned to each recommendation 
[9] (Tab. 1). To maintain agreement with pivotal 
studies and avoid confusion, the use of the 2009 
version of the FIGO classification in CC was main-
tained [10].
results and Discussion
41 of 89 radiation oncologists completed the dis-
tributed survey with recommendations for its vali-
dation, 33 of them routinely treat patients with CC. 
Within this group, the median number of patients 
with CC treated by each radiation oncologist was 
30 per year. Of a total of 19 radiation oncologists 
dedicated to gynaecology cancer in Chile, 17 re-
sponded to the survey (90%). The median number 
of CC patients treated by each of these experts was 
60 per year. 
table 1. level of evidence and grade of recommendation determined by the technical committee of explicit Guarantees in 
Health (GeS), Ministry of Health, chile
Grade Description
a
Highly recommended: Based on good quality studies
Systematic reviews of randomized clinical trials, randomized clinical trials, other systematic reviews with or without meta-
analysis, health technology assessment reports.
B
recommended: Based on moderate quality studies
randomized studies with methodological limitations or other forms of non-randomized controlled studies.
c
recommendation based exclusively on expert opinion or descriptive studies, case series, case reports or other uncontrolled 
studies with a high potential for bias.
i
Insufficient information
the available studies do not allow to establish the effectiveness or benefit / harm balance of the intervention, there are no 
studies on the subject or there is not enough consensus to consider that the intervention is supported by practice.
BP recommendation based on the experience and practice of a group of experts.
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The recommendations are summarized in the 
Table 2. The detail is available in Appendix.
Questions and brief analysis 
of evidence 
There are several international clinical guide-
lines on CC. We published here the first one, to 
our knowledge, developed in Latin America. There 
are consensuses that are oriented to the delinea-
tion of target volumes [11–13], specific topics in 
BT [14–17] and others related to multidisciplinary 
management of cervical CC [18–20]. Recently, 
the American Society for Radiation Oncology 
(ASTRO) has published a consensus focused on 
RT developed using a Delphi method with rec-
ommendations consistent with ours [21]. We fo-
cused on defining a desirable technical maximum 
and a required minimum in order to consider the 
existing differences and limitations in Chile and 
Latin America. In addition, we include a guideline 
regarding the indication of extended field radio-








the use of adjuvant eBrt is recommended in the following situations: WItHOUt 
platinum based cct: sedlis criteria: 1) ilv+ and deep third, any t 2) ilv+ middle 
third and tumor larger than 2 cm 3) ilv + superficial third and tumors greater than or 
equal to 5 cm 4) ilv–, middle third and tumor of 4 cm also 5) ilv+, deep third and 4 cm 
tumor. WItH platinum based cct: Peters criteria 1) lymphadenopathy (+) 
2) parametrium (+) 3) margin (+)
a 1 98%
IMrt technique in adjuvant Ebrt is recommended. conventional 3D technique is 
a valid option, considerations of a higher acute and late toxicity must be taken
B 1 86%
45 Gy in 25 fractions is recommended as adjuvant schedule dose
Other accepted fractionation schedules are 50.4 Gy in 28 fractions, 50 Gy in 25 
fractions of 2 Gy day, 46 Gy in 23 fractions
B 2 95%
routine use of brachytherapy as a boost dose in adjuvant setting is not 
recommended. its use can be considered in the case of a close or positive vaginal 
margin, for a  total eQD2 dose of 65–70 Gy
c 4 90%
the use of definitive radiotherapy (eBrt plus brachytherapy) is recommended in 
patients with an early stage (iB1, iia1) in the case of surgical contraindication 
or patient rejection 
B 1 100%
the use of definitive radiation therapy (external rt plus brachytherapy) with 
concomitant chemotherapy is recommended in patients with an advanced stage: 
iB2 and ≥ iia2 to iva
a 1 100%
3D conformal technique is recommended as standard for definitive radiotherapy
iMrt is an option to consider given its theoretical and clinical benefits derived from 
other pelvic neoplasms, with the use of an appropriate iGrt protocol  
and consideration of internal movements
B 3 81%
45 Gy in 25 fractions is recommended as definitive radiotherapy schedule dose
Other accepted fractionation schedules are 50.4 Gy in 28 fractions, 50 Gy in 25 
fractions, 46 Gy in 23 fractions
B 2 95%
total treatment time ≤ 50–56 days is recommended
early referral to Bt is recommended
a 2 100%
Parametrial boost with external radiation therapy is not recommended. For its 
omission consider: 1) clinical and imaging evaluation of parametrial involvement. 
2) to have the ability to perform interstitial brachytherapy if required
In case of not complying with the previous points, it is accepted to perform 
a sequential parametrial boost up to 54–59.4 Gy or its equivalent with integrated 
simultaneous boost, considering the increased risk of acute and mainly late 
complications
a 2 93%
the inclusion of lumbo-aortic (lao) lymph nodes is recommended in selected 
high-risk patients, according to the EMbrAcE II protocol: ≥ 1 common iliac lymph 
node matastases, ≥ 3 pelvic lymph node matastases. in the case of lymph node 
metastases in lao, it should be extended to at least 3 cm above the highest
B 3 85%
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therapy, parametrial boost, overall treatment time 
and the need to implement interstitial BT in facul-
ties involved in the treatment of patients with CC. 
A review of literature related with our recommen-
dations are presented below. 
what are the indications for adjuvant 
radiation therapy? 
Adjuvant radiotherapy (RT) in CC has been 
evaluated in different phase III clinical studies and 
meta-analyses, demonstrating that in patients with 
intermediate and high risk of recurrence there is 
a clear benefit with its use in terms of progres-
sion-free survival (PFS) and overall survival (OS) 
[22–26]. In relation to patients classified as in-
termediate risk based on the inclusion criteria of 
the GOG 92 study that considers lymph vascular 
invasion, depth of invasion and tumor size (“Sedlis 
criteria”), an increase in PFS was observed at 5 
years of 53% to 62% when comparing adjuvant RT 
versus surgery alone, with less local and distant 
recurrence [22, 23]. Regarding high-risk cases of 
postoperative recurrence, defined as those where 
there was compromise of lymph nodes, parame-
tria, or surgical margin in the radical hysterec-
tomy (“Peters criteria”), the GOG 109 study dem-
onstrated benefits of platinum based radiochemo-
therapy (RQT) versus RT alone with improvement 
in 5-year OS from 66% to 80% and in 5-year PFS 
from 79% to 83% [24, 25].
is intensity modulated radiation therapy 
(iMrt) better than conventional 3D 
treatment for adjuvant external beam 
radiotherapy?
The RTOG 1203 study [27] is the only random-
ized clinical trial that has evaluated the compari-
son between IMRT technique and conventional 3D 
conformal. It randomized 289 patients to conven-
tional 3D technique or IMRT in adjuvant setting, 
75% without concomitant chemotherapy. Initial re-
sults showed a significant decrease in acute and late 
gastrointestinal and genitourinary toxicity reported 
by patients [27, 28]. 
what is the appropriate dose 
and fractionation in adjuvant setting? 
The dose and fractionation used in the different 
clinical studies is variable. The protocols of the piv-
otal studies used for exclusive adjuvant EBRT 46 to 
50.4Gy in 23 to 28 fractions [22, 23], and in GOG 
109 study, planned RT to the pelvis in a scheme of 
49.3 Gy in 29 fractions, adding a lumboaortic nodal 
field of 45 Gy in 25 fractions in case of compro-
mised common iliac lymph nodes [24, 25]. Also, 
there are other studies that consider schemes from 








sequential boost to pelvic lymph node macroscopic disease is recommended up 
to 55–60 Gy or its equivalent with integrated simultaneous boost (SiB) (preferably SiB 
with iMrt technique)
In LAo lymph nodes macroscopic disease, without evidence of systemic spread 
on PEt/ct, sequential boost of up to 60 Gy or its equivalent with integrated 
simultaneous boost is recommended, ideally using the iMrt technique in both cases
B 2 100%
the use of HDr technique is recommended
lDr technique is accepted as an option
a 2 97%
Brachytherapy treatment planning based on 3D images (ct and/or Mri) with 
volumetric prescription and evaluation is recommended
Use applicator adapted to residual disease or anatomy of the patient. interstitial 
brachytherapy is recommended if required
2D dosimetry prescription a point and report rectal and bladder point accepted.  
in case of using the lDr technique, a prescription should be made for point a  
and a report of the rectal and bladder point should be made
a 2 98%
It is recommended to have an initial pelvic MrI evaluation (before Ebrt) and one 
immediately before brachytherapy. it can be a simulation Mri or fused diagnostic 
Mri. Prioritize Mri prior to brachytherapy. if there is no access to Mri, treatment based 
on simulation ct or ultrasound performed by an expert is accepted 
a 2 98%
eBrt — external beam radiotherapy; cct — concomitant chemotherapy; ilv — ipsilateral lung volume iMrt — intensity modulated radiation therapy;  
eQD2 — equivalent dose at fractionation of 2 Gy; iGrt — image-guided radiation therapy; HDr — high dose rate; lDr — low dose rate Pet — positron emission 
tomography;  ct — computed tomography; Mri — magnetic resonance imaging
Felipe Carvajal et al. radiotherapy for cc: chilean consensus of the society of radiation oncology
295https://journals.viamedica.pl/rpor
45 to 50.4 Gy between 1.8 and 2 Gy daily [29–31]. 
The IMRT protocol in adjuvant context (RTOG 
1203) allows the use of 45 Gy or 50.4 Gy in frac-
tions of 1.8 Gy daily depending on the researcher’s 
preference. Approximately 60% of patients received 
45 Gy in 25 fractions [27].
is the use of brachytherapy (Bt) boost 
recommended in the adjuvant setting?
Depending on the extent of surgical resection, 
the vaginal dome may be at higher risk of recur-
rence, but randomized clinical studies did not con-
sider BT boost in addition to EBRT [22–25],with 
only retrospective reports of its use in the context 
of patients with positive margins [32]. Considering 
the lack of evidence, the American Brachytherapy 
Society (ABS) generated a consensus on its use 
recommending adjuvant BT in addition to EBRT 
with an equivalent dose close to 70 Gy in patients 
with close or compromised vaginal margins, with 
non-radical hysterectomy, large or deeply invasive 
tumors, parametrial involvement or extensive lym-
phovascular invasion [14]. 
what are the indications for definitive 
radio(chemo)therapy?
In early stages (stages FIGO I to IIA1 except IB2) 
the usual treatment is surgery, but it is important 
to highlight that definitive RT offers similar results 
in terms of survival and therefore can be offered as 
an oncological equivalent alternative. A prospec-
tive randomized study [33, 34] with 170 patients 
in each arm in stages I–II found that there were no 
differences in 5-year survival between exclusive RT 
and surgery.
In locally advanced stages (FIGO stages IB2 
and IIA2 or higher), the evidence favors the use of 
definitive RTQT since the publication of the five 
classic randomized studies of the late 20th century 
[24, 35–38] that motivated the NCI alert and the 
meta-analysis published a decade later with up-
dated data from individual patients from 15 ran-
domized studies [39] again giving robust support to 
definitive RTQT as standard treatment in advanced 
stages.
is iMrt better than conventional 3D 
treatment for definitive eBrt?
Various retrospective [40–42] and prospective 
uncontrolled studies [43–45] and a meta-analysis 
[46], have shown equivalence in oncological re-
sults and a significant decrease in acute and chronic 
toxicity both genitourinary and gastrointestinal in 
benefit of the IMRT technique. However, there are 
no published randomized clinical trials confirming 
the benefits of using IMRT compared to conven-
tional 3D as definitive therapy.
what is the appropriate dose 
and fractionation of the eBrt 
in definitive radiotherapy?
The dose and fractionation used in different 
clinical studies during the EBRT phase is vari-
able, including patients from 40.8 Gy in 24 frac-
tions to 51 Gy in 30 fractions according to their 
FIGO stage [24, 35–38]. The American Brachy-
therapy Society guideline recommends 45 Gy in 
25 fractions [15]. On the other hand, the current 
ESGO/ESTRO/ESP guideline recommends a dose 
of 45–50.4 Gy in 1.8 Gy daily fractions [18, 47]. 
Retrospective studies have shown that most of 
the tumor response in the EBRT phase occurs 
before 45 Gy [48]. Three extra fractions to reach 
50.4 Gy provide little tumor control and, on the 
other hand, decrease the possibility of dose es-
calation during adaptive brachytherapy [48, 49. 
In this context, the GEC/ESTRO network in its 
EMBRACE studies [50] went from recommend-
ing a 45–50.4 Gy dose with EBRT (1.8 Gy daily 
fractions) to a 45 Gy dose in 25 fractions for all 
patients in the EMBRACE II protocol [51]. 
is there an overall treatment time 
that determines the best oncological 
outcome?
The overall treatment time impact was demon-
strated in studies prior to the concomitant  che-
motherapy era showing a pelvic control loss of 
7–8% per extra week [52–55]. Considering the 
above, the American Brachytherapy Society rec-
ommends that the total treatment time should not 
exceed 8 weeks [15]. This data has been corrobo-
rated at the concomitant chemotherapy era by the 
EMBRACE group who showed that, considering 
a median of 49 days of treatment, an extra week is 
equivalent to 1–2.5% local control loss depending 
on the size of the residual tumor volume. Consid-
ering the previous data, the EMBRACE II group 
recommends maintaining a total treatment time 
of ≤ 50 days [56]. 
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what is the role of parametrial boost 
in definitive radiation therapy?
Parametrial boost with EBRT has not been used 
routinely or standardized in clinical trials [24, 
35–38]. It has been observed that its application 
leads to unpredictable doses at the tumor and the 
organs at risk [57] which can lead to a decrease 
in local control and increased toxicity. An Austra-
lian retrospective study evaluating the omission of 
external beam parametrial boost in patients with 
parametrial involvement defined by physical ex-
amination and magnetic resonance showed no dif-
ference in terms of local control compared to the 
group of patients without parametrial involvement 
[58]. In the last decade the trend has been to im-
plement 3D image guided adaptive brachytherapy 
with parametrial boost application as needed at the 
brachytherapy planning, being the current recom-
mendation of the GEC-ESTRO network. Current 
ESGO/ESTRO/ESP guidelines advise against the 
use of parametric treatment with external radio-
therapy beyond 45–50.4 Gy [47]. 
what is the role of extended field 
radiotherapy (lumboaortic area) 
in definitive radiotherapy? 
In cervical cancer patients it is estimated that 
the probability of pelvic and lumboaortic nodal 
involvement increases progressively as the disease 
stage progresses affecting overall survival (OS) 
and disease-free survival (DFS) [59]; therefore, ad-
equate staging is essential for treatment planning. 
Current international guidelines consider FDG 
PET-CT as the preferred option for staging given 
its high specificity (approx. 90%) and sensitivity 
(approx. 70%) in patients with advanced local in-
volvement [18, 60, 61]. The benefit of prophylactic 
extended field towards the lumboaortic region in 
patients without compromise in that zone has been 
evaluated in several studies (including EORTC 
1988 and RTOG 7920), demonstrating contradic-
tious improvement in OS and no benefit in other 
studies. However, treatment in these studies was 
not performed with concomitant chemotherapy, so 
the actual benefit may be overestimated [62–65]. 
Regarding patients with compromised lumboaortic 
nodes, the contribution of extended field versus 
pelvic field is also controversial, since the clinical 
trial that studied it (RTOG 9001) did not include 
CT in patients with extended field but it did for 
those treated exclusively with a pelvic field [37, 66]. 
More current retrospective studies report benefit 
in DFS and local control with acceptable toxicity 
[67], but it’s not clear what the characteristics of pa-
tients who should receive this modality are. Vargo 
et al. showed that extended field IMRT achieves 
95% control in lumboaortic-negative patients and 
89% in lumboaortic-positive patients [68]. The EM-
BRACE group showed that at the time of diagnosis 
47% of the patients had nodal involvement, mainly 
in the pelvis (internal, external and common iliac 
region), but nodal recurrences after treatment gen-
erally occurred in the lumboaortic region constitut-
ing 69% of all nodal failures. Of these failures, 78% 
had not received RT in that region, so identifying 
high-risk groups to treat is essential [50]. Due to 
all of the above, the EMBRACE II group defined 
a high-risk lumboaortic recurrence or distance fail-
ure group: those patients who have 1 or more com-
mon iliac lymphadenopathy or those with the pres-
ence of 3 or more pelvic lymphadenopathy, with the 
aim to study the role of  lumboaortic RT in those 
who meet these requirements.
In cases with a lumboaortic involment, a paraor-
tic field covering at least 3 cm cephalic to the ad-
enopathy will be planned. 
It’s clear that the available evidence is not cat-
egorical for the use of extended lumboaortic field, 
so the proposed plan is to follow the rationale of 
the main research group active in the subject (EM-
BRACE II) [50].
is there an optimal dose to deliver 
in macroscopic node disease?
There are retrospective studies that have evalu-
ated the dose necessary to achieve adequate con-
trol of macroscopic lymph node disease [69–71]. 
These studies, have shown that a dose of ≥ 57.5 Gy 
achieves a better oncological outcome. It is impor-
tant to consider, in this context, that brachytherapy 
also provides doses to the lymph node areas, mainly 
to the iliac-obturator region, being able to add up 
to 5 Gy on average. In the case of lumbo-aortic 
lymphadenopathy, extended field irradiation has 
been performed with a dose of 45 Gy in 25 frac-
tions of 1.8 Gy [37, 62, 63, 65–67]. Boost dose to 
the lymphadenopathy have been performed with 
doses of up to 60 Gy in conventional fractionation, 
considering studies that show a better nodal control 
with doses ≥ 57.5 Gy [69]. For pelvic macroscopic 
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node disease, current ESTRO guidelines recom-
mend a dose of 55–60 Gy considering the contribu-
tion of brachytherapy [47]. 
is HDr brachytherapy technique better 
than lDr brachytherapy?
Both techniques are similar from the perspective 
of oncological outcome and toxicity of the treat-
ment. However, the HDR technique has some ad-
vantages over LDR [72–76] as it:
• allows better positioning of the applicator in the 
patient during the treatment session;
• enables image-guided treatment;
• allows an outpatient treatment, unlike LDR 
brachytherapy that requires hospitalization (1–3 
days);
• decreases the risk of complications due to im-
mobilization of the patient;
• decreases the risk of radiation exposure to per-
sonnel;
• decreases the risk of radioactive accidents.
In this context, the International Atomic Ener-
gy Organization has had among its objectives that 
radiotherapy faculty have a transition from LDR 
brachytherapy to HDR [77]. 
is 3D treatment planning better than 2D 
in brachytherapy?
Image-guided (3D) treatment allows evaluating 
the response to treatment during radiotherapy and 
adapting the volumes to be treated with brachyther-
apy. The STIC Trial, a non-randomized prospective 
study, shows that a 3D based treatment planning in 
cervical cancer allows better local control and lower 
toxicity rate than 2D dosimetry [78]. Currently, the 
Groupe Européen de Curiethérapie of the European 
Society for Radiation Oncology (GEC-ESTRO) rec-
ommends the Magnetic Resonance-guided Brachy-
therapy technique [16]. In 2008, the GEC-ESTRO 
began the study “International Study on MRI-Based 
Brachytherapy in Cervical Cancer” (EMBRACE) 
[50] reaching the recruitment of > 1,300 patients 
in 27 countries in 2015. Pending its results, in 2010 
the GEC-ESTRO started the retrospective study 
RetroEMBRACE, whose data shows that the local 
control at 5 years is 89%. The concept of adaptive 
radiation therapy is focused on the volume of the 
primary tumor (GTV-T) and how it changes during 
RQT [79–81]. To achieve adequate doses, the com-
bination of intracavitary and interstitial applicators 
(IC/IS) is essential in large tumors, seeking to in-
crease the dose in tumor tissue without increasing 
the toxicity of organs at risk (OAR) [82–85].
what is the contribution of 3D images 
for the brachytherapy treatment 
planning?
Sectional images (CT or MRI) provide valid and 
reliable information on the extent and configura-
tion of individual tumors and their topography, 
making it easier to define the volumes to be treated 
(compared to clinical examinations without imag-
ing support). By providing greater precision regard-
ing the extension and spatial arrangement of the 
target, 3D images allow to increase the treatment 
dose in high-risk areas, protecting organs at risk 
near the tumor. The main advantage of MRI is its 
superior quality in the representation of soft tissues; 
therefore, when it is  available, MRI is the imaging 
method of choice as it allows better differentiation 
between tissues, estimating parametrial involve-
ment and tumor size [16, 17, 86–90]. 
conclusion
The recommendations presented are the result of 
the discussion of the evidence among national gy-
naecological radiotherapy specialists. Radiotherapy 
continues to play a fundamental role in the curative 
treatment of cervical cancer, whether as definitive 
therapy or adjunctive to surgery, concomitant or 
not with chemotherapy. To optimize the manage-
ment of this pathology, it is recommended that new 
diagnostic modalities, such as PET-CT and MRI 
which allow a better selection of patients who will 
benefit from radiotherapy treatment with curative 
intent, should be incorporated as well as planning 
and adaptation of the treatment corrected. The op-
timal treatment should be carried out in a period 
not exceeding 56 days and, ideally, in less than 50 
days, which is a quality standard that requires to ar-
ticulate human resources in comprehensive cancer 
centres and foster homes, among others. Regard-
ing the radiotherapy technique, the use of IMRT 
is recommended as a treatment option when to 
reduce the dose to organs at risk. The need to mi-
grate to an adaptive 3D image based brachytherapy 
technique with an interstitial support option is em-
phasized. These recommendations are available to 
standardize and improve clinical practice and must 
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be adapted to each radiotherapy centre according 
to its local reality.
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